TG Therapeutics Presented Updated Data From The ENHANCE Phase 3b Trial Evaluating BRIUMVI (Ublituximab-xiiy) In Patients With Relapsing Forms Of Multiple Sclerosis (RMS)
TG Therapeutics Presented Updated Data From The ENHANCE Phase 3b Trial Evaluating BRIUMVI (Ublituximab-xiiy) In Patients With Relapsing Forms Of Multiple Sclerosis (RMS)
tg therapeutics在ENHANCE第30億試驗中發佈了評估BRIUMVI (Ublituximab-xiiy)在複發性多發性硬化 (RMS)患者中的更新數據
TG Therapeutics Presented Updated Data From The ENHANCE Phase 3b Trial Evaluating BRIUMVI (Ublituximab-xiiy) In Patients With Relapsing Forms Of Multiple Sclerosis (RMS)
tg therapeutics在ENHANCE第30億試驗中發佈了評估BRIUMVI (Ublituximab-xiiy)在複發性多發性硬化 (RMS)患者中的更新數據
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間